Vanguard Investments Australia
MYGN icon

Vanguard Investments Australia’s Myriad Genetics MYGN Stock Holding History

Vanguard Investments Australia’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-20,580
Closed -$92.6K – 2410
2026
Q1 		$92.6K Buy
+20,580
New +$107K ﹤0.01% 2292

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Vanguard Investments Australia's MYGN Position: Q2 2026 in Review

Vanguard Investments Australia sold out of Myriad Genetics (MYGN) in Q2 2026, closing a stake of 20,580 shares — an estimated $92.6K sold.

Vanguard Investments Australia first reported a position in MYGN in Q1 2026 and held it in 1 quarter. The position peaked at $92.6K in Q1 2026. 183 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Vanguard Investments Australia reported no remaining Myriad Genetics position as of Q2 2026 after selling out during the quarter.
  • Vanguard Investments Australia sold 20,580 Myriad Genetics shares in Q2 2026, an estimated $92.6K.
  • Vanguard Investments Australia first reported a position in Myriad Genetics in Q1 2026 and held it in 1 quarter.
  • Vanguard Investments Australia's Myriad Genetics position peaked at $92.6K in Q1 2026.
  • 183 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Vanguard Investments Australia's 13F filing for Q2 2026, filed 13 Aug 2026.